LY3372689 is a drug candidate molecule under investigation to treat Alzheimer's disease. It targets the enzyme O-GlcNAcase.[1] Its result is to reduce formation of tau protein tangles.
![]() | |
Names | |
---|---|
IUPAC name N-[4-fluoro-5-[[2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide | |
Identifiers | |
3D model (JSmol) | |
PubChem CID | |
| |
| |
Properties | |
C16H22FN5O3S | |
Molar mass | 383.44 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
A molecule containing radioactive fluorine was used with a PET scan to show that LY3372689 binds in the human brain.[2]
Eli Lilly and Company is recruiting subjects for a clinical trial.[3] Some hospitals in Australia: St Vincent's Hospital, SydneyHornsby Ku-Ring-Gai Hospital, The Prince Charles Hospital, The Queen Elizabeth Hospital, Adelaide, Box Hill Hospital, and Delmont Private Hospital are involved.[4] Results of the trial are expected by June 2024.[5]
Chemical
The molecule contains three rings: thiazole, piperidine and oxadiazole. Other functional groups included are an ether, acetamide, and a fluoride.[6]